Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000334678 | SCV000329633 | pathogenic | not provided | 2022-07-07 | criteria provided, single submitter | clinical testing | Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 31216405, 32827181, 12070251) |
Baylor Genetics | RCV000850544 | SCV000992755 | likely pathogenic | Rubinstein-Taybi syndrome due to CREBBP mutations | 2017-12-31 | criteria provided, single submitter | clinical testing | |
3billion | RCV000850544 | SCV002058983 | likely pathogenic | Rubinstein-Taybi syndrome due to CREBBP mutations | 2022-01-03 | criteria provided, single submitter | clinical testing | Same nucleotide change resulting in same amino acid change has been previously reported as pathogenic/likely pathogenic with strong evidence (ClinVar ID: VCV000279963, PMID:31216405, PS1_S). It is not observed in the gnomAD v2.1.1 dataset (PM2_M). In silico tool predictions suggest damaging effect of the variant on gene or gene product (REVEL: 0.973, 3CNET: 0.99, PP3_P). Therefore, this variant is classified as likely pathogenic according to the recommendation of ACMG/AMP guideline. |
Wessex Regional Genetics Laboratory, |
RCV000850544 | SCV000999467 | likely pathogenic | Rubinstein-Taybi syndrome due to CREBBP mutations | 2019-11-05 | no assertion criteria provided | clinical testing |